| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/04/2008 | CN100391473C Pretreating liquid and freeze protecting liquid for cryopreservation of erythrocyte and their application |
| 06/04/2008 | CN100391471C Method for preparing platinum metal bunch with biological activity, and use thereof |
| 06/04/2008 | CN100391464C Pharmaceutical compositions comprising active vitamin D compounds |
| 06/04/2008 | CN100391462C Enhanced drug delivery in transdermal systems |
| 06/04/2008 | CN100391460C Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
| 06/04/2008 | CN100391459C Doxazosin mesilate slow releasing preparation |
| 06/04/2008 | CN100391458C Preparation method of ziprasidone or its salt inclusion |
| 06/04/2008 | CN100391456C Beta-cyclodextrin / amoxicillin inclusion compound and its composition with clavulanic kalium and preparation method thereof |
| 06/04/2008 | CN100391454C Preparation of hydrobromic acid dextro methaphen and beta cyclodeatrin compounding object |
| 06/04/2008 | CN100391445C Novel 'burst-free' sustained release poly-(lactide/glycolide) mi crospheres |
| 06/04/2008 | CN100391441C Matrine elaioplast drop ball and its preparation method |
| 06/04/2008 | CN100391440C Formulation based on heparin, glycosaminogl ycan or heparinoid, use of the formulation and the formulation base |
| 06/04/2008 | CN100391439C Immunopotentiators |
| 06/04/2008 | CN100391438C Process for making aqueous coated beadlets |
| 06/04/2008 | CN100391437C GM-CSF targeted medicine liposome for resisting acute myelogenous leukemia and preparation method thereof |
| 06/04/2008 | CN100391354C Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis |
| 06/03/2008 | US7381805 Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF |
| 06/03/2008 | US7381796 Dried blood factor composition comprising trehalose |
| 06/03/2008 | US7381751 Mixture of silicone resin with chelate compound, pigemnt and lubricant; molding |
| 06/03/2008 | US7381740 Melatonin analogue prodrugs |
| 06/03/2008 | US7381702 Methods of treating diabetes mellitus |
| 06/03/2008 | US7381560 Administering a chimeric anti-CD20 antibody; hybridomas; monoclonal antibodies |
| 06/03/2008 | US7381426 Therapy for bone disorders |
| 06/03/2008 | US7381425 Preservation of bioactive materials by freeze dried foam |
| 06/03/2008 | US7381424 Hydrostatic delivery system for controlled delivery of agent |
| 06/03/2008 | US7381422 Mixing cationic surfactant, a polyoxyethylene and polyoxypropylene block copolymer and a polynucleotide at a temperature below the cloud point of said block copolymer to form a mixture; cold filtering the mixture to produce a sterile formulation |
| 06/03/2008 | US7381420 Labeling reactant |
| 06/03/2008 | US7381418 Methylene-containing copolymer of an unsaturated hydrocarbon monomer such as alpha-olefin, diolefin or cyclic olefin and an acrylic or vinyl monomer or having polyether, polylactone or polyester units; crosslinked with a radiation dose of at least 10,000 rads |
| 06/03/2008 | US7381404 Treatment for dry macular degeneration |
| 06/03/2008 | CA2536069C Use of green porphyrins in ocular diagnosis and therapy |
| 06/03/2008 | CA2350430C Method and apparatus for liposome production |
| 06/03/2008 | CA2346016C Glucoside paucilamellar vesicles |
| 06/03/2008 | CA2326356C Oral liquid antidepressant solution |
| 06/03/2008 | CA2261018C Treatment and diagnosis of cancer |
| 06/03/2008 | CA2256118C Animal feed pelleting process and animal feed pellets produced therefrom |
| 06/03/2008 | CA2244664C Composition comprising interleukin-1 inhibitor and controlled release polymer |
| 06/03/2008 | CA2228610C Controlled release products |
| 06/03/2008 | CA2201725C Composition, device and method for electrotransport agent delivery |
| 06/03/2008 | CA2178144C Stabilized aqueous liquid preparations of blood coagulation factor xiii |
| 05/29/2008 | WO2008063634A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 05/29/2008 | WO2008063581A2 Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| 05/29/2008 | WO2008063024A1 Inclusion complex of sibutramine and beta-cyclodextrin |
| 05/29/2008 | WO2008062909A1 ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE |
| 05/29/2008 | WO2008062908A1 Method for producing particles and particles |
| 05/29/2008 | WO2008062861A1 Extract powder of indigo-containing plant, method for production thereof, and use thereof |
| 05/29/2008 | WO2008062842A1 Sodium salt of disaccharide compound, method for producing the same, and use of the same |
| 05/29/2008 | WO2008062840A1 Method for removing organic solvent |
| 05/29/2008 | WO2008062814A1 Hydrogen-dissolved aqueous solution and method for prolonging the life duration of hydrogen dissolved in the aqueous solution |
| 05/29/2008 | WO2008062699A1 Carrier |
| 05/29/2008 | WO2008062481A2 Formulations of peg-interferon alpha conjugates |
| 05/29/2008 | WO2008062437A2 Process for the preparation of sevelamer hydrochloride and formulation thereof |
| 05/29/2008 | WO2008062435A2 Stabilised dosage forms of amlodipine besylate |
| 05/29/2008 | WO2008062209A2 Dissolution and processing of cellulose |
| 05/29/2008 | WO2008061677A1 Transdermal therapeutic system comprising ion pair micro-reservoirs |
| 05/29/2008 | WO2008061639A1 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 05/29/2008 | WO2008061427A1 Dihydrazide compounds, preparation and uses thereof |
| 05/29/2008 | WO2008061409A1 Enteric coated formulation comprising alkaline active agent and its preparation process |
| 05/29/2008 | WO2008061375A1 Antiseptic |
| 05/29/2008 | WO2008061355A1 Glp-1 depot systems, and methods of manufacture and uses thereof |
| 05/29/2008 | WO2008043081A3 Liquid chalcogenide compositions and methods of manufacturing and using the same |
| 05/29/2008 | WO2008041246A3 Injectable depot composition and its' process of preparation |
| 05/29/2008 | WO2008036847A3 Self preserved aqueous pharmaceutical compositions |
| 05/29/2008 | WO2008020820A3 Pharmaceutical compositions comprising aripiprazole |
| 05/29/2008 | WO2007127668A3 Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| 05/29/2008 | WO2007120693A3 Targeted binding agents directed to upar and uses thereof |
| 05/29/2008 | WO2007113665A3 Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides |
| 05/29/2008 | WO2007034210A8 Deglycosylated anti-muc-1 antibodies and uses thereof |
| 05/29/2008 | WO2006100484A3 Deliver of molecules to a li id bila |
| 05/29/2008 | US20080125498 Treatment of neurodegenerative diseases and conditions using par1 antagonists |
| 05/29/2008 | US20080125491 screening for neuroprotectants such as -Isobutyryl-1,4-a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid amide, used for the prevention of neurodegenerative diseases and cardiovascular disorders |
| 05/29/2008 | US20080125482 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same |
| 05/29/2008 | US20080125404 purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone |
| 05/29/2008 | US20080125369 Soluble t cell receptors |
| 05/29/2008 | US20080125356 Stable Growth Hormone Liquid Formulation |
| 05/29/2008 | US20080125350 Branched polyalkylene glycols |
| 05/29/2008 | US20080125349 Biocompatible polymer such as glycolic acid-lactic acid copolymer having dispersed therein a polypeptide and a sugar, for release of said peptide such as exendin-4 |
| 05/29/2008 | US20080125348 Biocompatible glycolic acid-lactic acid copolymer with a polypeptide and a sugar; drug delivery of peptide drugs such as exendin-4; improves bioavailability, patient compliance |
| 05/29/2008 | US20080124780 Microarray comprising semipermeable matrix for use in monitoring drug metabolism |
| 05/29/2008 | US20080124473 Silk fibroin from domesticated silkworm; sustained release; waste treatment |
| 05/29/2008 | US20080124396 polymer synthesized by a cross-coupling reaction of polymer scaffold units and xenoantigens |
| 05/29/2008 | US20080124395 Formulations and devices for treatment or prevention of neural ischemic damage |
| 05/29/2008 | US20080124393 Time-release agent containing poorly soluble agent such as clozapine; release the agent following administration for a time period ranging from about 2 to about 24 hours or longer |
| 05/29/2008 | US20080124390 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily |
| 05/29/2008 | US20080124386 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 05/29/2008 | US20080124377 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 05/29/2008 | US20080124372 Morphology profiles for control of agent release rates from polymer matrices |
| 05/29/2008 | US20080124350 Nanoparticle-based vaccine delivery system containing adjuvant |
| 05/29/2008 | US20080124347 Insulinotropic peptide conjugate using carrier substance |
| 05/29/2008 | US20080124307 Method for promoting immunotherapy |
| 05/29/2008 | US20080124275 Crystalline Form of Fatty Acid Amide Hydrolase (Faah) |
| 05/29/2008 | CA2671437A1 Targeted delivery of therapeutic agents with lyophilized matrices |
| 05/29/2008 | CA2670619A1 Dissolution and processing of cellulose |
| 05/29/2008 | CA2669705A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 05/29/2008 | CA2669674A1 Sodium salt of disaccharide compound, method for producing the same, and use of the same |
| 05/29/2008 | CA2669347A1 Methods for treating pompe disease |
| 05/29/2008 | CA2669308A1 Transdermal therapeutic system comprising ion pair micro-reservoirs |
| 05/29/2008 | CA2662510A1 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 05/29/2008 | CA2661172A1 Programmable buoyant delivery technology |
| 05/29/2008 | CA2657829A1 Particles for delivery of active ingredients, process of making and compositions thereof |
| 05/28/2008 | EP1925324A1 Hydrogel Adhesives for Use on Hair or Fiber-Populated Surfaces |